The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ
Official Title: MammoSite Radiation Therapy System (RTS) as the Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ (DCIS)
Study ID: NCT00586326
Brief Summary: This study has been designed to compile information on the efficacy of the MammoSite RTS providing sole radiation therapy for patients with pure DCIS.
Detailed Description: Data relevant to the evaluation of the efficacy and safety of the MammoSite RTS system in providing radiation therapy to patients with DCIS will be collected. The MammoSite is a radionuclide applicator designed to deliver internal radiation therapy (brachytherapy) in patients with breast tumors following breast tumor resection surgery (lumpectomy).
Minimum Age: 45 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Arizona Oncology Services, Phoenix, Arizona, United States
Daniel Freeman Hospital, Inglewood, California, United States
University of Southern California, Los Angeles, California, United States
Cedars Medical Center, Miami Beach, Florida, United States
St. Agnes Hospital, Baltimore, Maryland, United States
William Beaumont Hospital, Royal Oak, Michigan, United States
NY Presbyterian, New York, New York, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Rhode Island Hospital, Providence, Rhode Island, United States
MD Anderson Cancer Clinic, Houston, Texas, United States
Virginia Commonwealth University, Richmond, Virginia, United States
Swedish Cancer Institute, Seattle, Washington, United States
Name: Oscar Streeter, MD
Affiliation: University of Southern California
Role: PRINCIPAL_INVESTIGATOR